Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefit will not be confirmed by a Phase 3 clinical trial, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of a Phase 3 clinical trial, the timing and costs of clinical trials and regulatory approvals will be different than management currently anticipates, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... San Francisco, California (PRWEB) October 01, 2014 ... grant from the National Science Foundation to expand their ... approaches to build and modify DNA. The Small Business ... help commercialize the “j5” technology under exclusive license from ... the Joint BioEnergy Institute , an LBNL laboratory ...
(Date:10/1/2014)... , October 1, 2014 ... software invited to engage around the theme, ,Commercial Opportunities ...   Elsevier , a ... and services, will host a gathering of some of ... and trends impacting healthcare today and in the future. ...
(Date:9/30/2014)... This news release is available in German . ... at the Technische Universitt Mnchen (TUM) have demonstrated a ... Their experiments show that future computer chips could be ... transistors. As the main enabling technology of the semiconductor ... fundamental limits, the TUM researchers and collaborators at the ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... made of clay and a bit of high-grade plastic draws oil ... lab tests show that oil absorbed can be squeezed back out ... the material, called an aerogel, believe it will effectively clean up ... and roadways, rivers and oceans. , The EPA estimates that 10 ...
... Feb. 4, 2010 -- Four Oak Ridge National Laboratory ... five-year research grants as part of the Department of ... million program, funded under the American Recovery and Reinvestment ... to support exceptional researchers during the crucial early career ...
... , , IPSWICH, Mass. ... to the Wellcome Trust Sanger Institute, New England Biolabs is ... England Biolabs as one of its suppliers for next-generation sequencing ... "We are extremely pleased that the Wellcome Trust Sanger Institute, ...
Cached Biology Technology:New material absorbs, conserves oil 24 ORNL researchers selected for Recovery Act early career funds 24 ORNL researchers selected for Recovery Act early career funds 3Wellcome Trust Sanger Institute to use NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for Next Generation Sequencing 2
(Date:9/30/2014)... do seedless watermelon, salmon, and strawberries all have in ... two sets of chromosomes and are diploid, these organisms ... sets of chromosomesseedless watermelon and salmon have 3 and ... While this might seem surprising, in fact most ... first discovered over a century ago, but only recently, ...
(Date:9/30/2014)... A team of environmental scientists and engineers, led ... awarded a three-year, $5.25 million grant from the ... Competitive Research to make a direct positive impact ... remediation and disposal of radioactive contaminants. , "Understanding ... adequately dealing with environmental aspects of nuclear technologies ...
(Date:9/30/2014)... is available in German . ... the most expensive foods in the world. Because they grow ... But the distinctive smell of truffles is not only of ... under the direction of the Goethe University Frankfurt have discovered ... soil bacteria which are trapped inside truffle fruiting bodies. , ...
Breaking Biology News(10 mins):Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Researchers get $5.25 million to advance nuclear technologies in South Carolina 2On the trail of the truffle flavor 2
... The biggest ever single UK public investment in bioenergy ... main funding agency for the biosciences the Biotechnology ... 27M BBSRC Sustainable Bioenergy Centre has been launched to ... and emerging UK sustainable bioenergy sector and to ...
... Switzerland, Jan. 26 SVOX, the leading provider ... the Professional,Speech Processing Group of Siemens AG, according ... speech technology-related IP of Siemens AG developed,over 25 ... more than 60 patent families. The majority of ...
... Spring Harbor Laboratory (CSHL) announced today the discovery of ... time, they reported that their discovery suggests the presence ... in which these and possibly other small RNAs are ... project called ENCODE, also provided information concerning the biological ...
Cached Biology News:Biggest ever public investment in bioenergy to help provide clean, green and sustainable fuels 2SVOX Acquires Speech Processing Unit of Siemens AG, Expands Into Speech Recognition and Speech Dialog 2CSHL scientists find a new class of small RNAs and define its function 2CSHL scientists find a new class of small RNAs and define its function 3
Request Info...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
Biology Products: